Back to results
US 11,376,248 B2Granted
Treatment of aneurysms
AssigneeGeorgia State University Research Foundation, Inc.
InventorMing-Hui Zou
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeGeorgia State University Research Foundation, Inc.
InventorMing-Hui Zou
Estimating the term…
The present invention provides methods for detecting and/or treating a subject having an aneurysm or at risk for developing an aneurysm. It has been discovered that a key metabolite of the kynurenine (Kyn) pathway, a major route for the metabolism of essential amino acid tryptophan (Trp) into nicotinamide adenine dinucleotide (NAD+), plays a critical role in the formation of aneurysms, for example abdominal aortic aneurysms. In particular, it has been discovered that 3-Hydroxyanthranilic acid (3-HAA), a product of kynureninase (KYNU), plays a causative role in the formation of aneurysms by, for example exerting pro-inflammatory effects on vascular smooth muscle cells. It has further been discovered that elevated levels of 3-HAA are indicative of the presence and/or progression of an aneurysm, and 3-HAA levels correlate with the size (aortic diameter) of the aneurysm.
A method of treating a subject with an aneurysm comprising administering to the subject an effective amount of a KYNU inhibitor, a KMO inhibitor, a 3-HAO upregulator, or acipimox, wherein the aneurysm is an abdominal aortic aneurysm (AAA).
A method of reducing the risk of an aortic dissection in a subject having an underlying medical condition which predisposes the subject to the sudden dissection of an artery comprising administering to the subject an effective amount a KYNU inhibitor, a KMO inhibitor, a 3-HAO upregulator, or acipimox.
A method of treating an aneurysm in a subject comprising:
A method of treating a subject with an aneurysm consisting of administering to the subject an effective amount of a KYNU inhibitor, a KMO inhibitor, a 3-HAO upregulator, or acipimox.
Dependencies are inferred from the claim text.